Astrazeneca has pushed back the release of results for a key lung cancer drug trial
Astrazeneca has pushed back the release of results for a key lung cancer drug trial.
The pharmaceuticals giant originally said the findings would be revealed in the first half of 2018 but said yesterday they will be announced in the second half.
Known as ‘Mystic’, the trial will show whether its Imfinzi drug gives patients with non-small cell lung cancer a better chance of survival.
Initial results in July showed a combination of Imfinzi with another drug, tremelimumab, was no more effective than chemotherapy, sending shares plunging by 16 per cent in a day.
Astra said: ‘Based on current predictions, the final analysis of overall survival is now expected in the second half of 2018, previously anticipated in the first half.’
The Mystic trial is being conducted at 167 facilities across 17 countries.
Lung cancer is the biggest cause of cancer death among men and women, accounting for roughly one third of deaths related to the disease.
THIS IS MONEY’S FIVE OF THE BEST SAVINGS DEALS